Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium

Journal of Ovarian Research

Jalid Sehouli³  Sven Mahner⁵  Ignace Vergote²  Robert Zeillinger⁶  Nicole Concin¹  Dan Cacsire Castillo-Tong⁶  Alain Zeimet¹  Paul Speiser⁶  Els van Nieuwenhuysen²  Radoslav Chekerov³  Sandrina Lambrechts²  Ioana Braicu³  Christine Eulenburg⁴  Linn Woelber⁵  Fabian Trillsch⁵ 

[1] Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria;Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium;Department of Gynecology, European Competence Center for Ovarian Cancer; Campus Virchow Klinikum, Charité – Universitätsmedizin Berlin, Berlin, Germany;Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg, 20246, Germany;Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria

关键词: Performance status;    Chemotherapy;    Surgery;    Elderly;    Prognosis;    Ovarian cancer;   

Others  :  810425
DOI  :  10.1186/1757-2215-6-42

 received in 2013-04-09, accepted in 2013-06-19,  发布年份 2013

【 摘 要 】

Background

Approximately one third of women diagnosed with ovarian cancer is 70 years or older. Information on the treatment reality of these elderly patients is limited.

Methods

275 patients with primary epithelial ovarian cancer FIGO stage II-IV undergoing cytoreductive surgery and platinum-based chemotherapy were prospectively included in this European multicenter study. Patients <70 and ≥70 years were compared regarding clinicopathological variables and prognosis.

Results

Median age was 58 years (18–85); 47 patients (17.1%) were 70 years or older. The postoperative 60-day-mortality rate was 2.1% for elderly and 0.4% for younger patients (p < 0.001). Elderly patients were less likely to receive optimal therapy (no residual disease after surgery and platinum combination chemotherapy) compared to patients <70 years (40.4% vs. 70.1%, p < 0.001) and their outcome was less favorable regarding median PFS (12 vs. 20 months, p = 0.022) and OS (30 vs. 64 months, p < 0.001). However, in multivariate analysis age itself was not a prognostic factor for PFS while the ECOG performance status had prognostic significance in elderly patients.

Conclusions

Elderly patients with ovarian cancer are often treated less radically. Their outcome is impaired despite no consistent prognostic effect of age itself. Biological age and functional status should be considered before individualized treatment plans are defined.

【 授权许可】

   
2013 Trillsch et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Yancik R, Ries LA: Cancer in older persons: an international issue in an aging world. Semin Oncol 2004, 31:128-136.
• [2]Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, et al.: SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). In Book SEER Cancer Statistics Review, 1975–2009. Edited by Vintage 2009 Populations. Bethesda, MD: City: National Cancer Institute; 2012.
• [3]Hilpert F, Wimberger P, du Bois A, Pfisterer J, Harter P: Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience. Onkologie 2012, 35:76-81.
• [4]du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009, 115:1234-1244.
• [5]Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:3621-3627.
• [6]Maas HA, Kruitwagen RF, Lemmens VE, Goey SH, Janssen-Heijnen ML: The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 2005, 97:104-109.
• [7]Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, Teng NN, Kapp DS, Berek JS, Leiserowitz GS: Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer 2006, 95:1314-1320.
• [8]Jorgensen TL, Teiblum S, Paludan M, Poulsen LO, Jorgensen AY, Bruun KH, Hallas J, Herrstedt J: Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol 2012, 127:367-374.
• [9]Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S, Zeillinger R, et al.: Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: Results from the OVCAD study. Gynecol Oncol 2012, 128:245-251.
• [10]Pils D, Hager G, Tong D, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, et al.: Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium. Cancer Sci 2012, 103:1334-1341.
• [11]Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, Woelber L, Cadron I, Van Gorp T, Zeillinger R, et al.: Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer 2012, 22:380-385.
• [12]Rustin GJ: Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003, 21:187s-193s.
• [13]Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, Lacombe D, Monfardini S, Scalliet P, Wildiers H: EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 2010, 46:1502-1513.
• [14]Massarweh NN, Legner VJ, Symons RG, McCormick WC, Flum DR: Impact of advancing age on abdominal surgical outcomes. Arch Surg 2009, 144:1108-1114.
• [15]Gerestein CG, Damhuis RA, Burger CW, Kooi GS: Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol 2009, 114:523-527.
• [16]Thrall MM, Goff BA, Symons RG, Flum DR, Gray HJ: Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly. Obstet Gynecol 2011, 118:537-547.
• [17]Diaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Gordon TA, Armstrong DK, Bristow RE: Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol 2005, 99:352-357.
• [18]Woelber L, Jung S, Eulenburg C, Mueller V, Schwarz J, Jaenicke F, Mahner S: Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol 2010, 36:583-588.
• [19]Peiretti M, Zanagnolo V, Aletti GD, Bocciolone L, Colombo N, Landoni F, Minig L, Biffi R, Radice D, Maggioni A: Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol 2010, 119:259-264.
• [20]Hilpert F, du Bois A, Greimel ER, Hedderich J, Krause G, Venhoff L, Loibl S, Pfisterer J: Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged > or = 70 years with advanced ovarian cancer–a study by the AGO OVAR Germany. Ann Oncol 2007, 18:282-287.
• [21]Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G: Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 2007, 25:1858-1869.
• [22]Mahner S, Oskay-Ozcelik G, Heidrich-Lorsbach E, Fuxius S, Sommer H, Klare P, Belau A, Ruhmland B, Heuser T, Kolbl H, et al.: A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. J Cancer Res Clin Oncol 2012, 138:1413-1419.
• [23]Braicu I, Fotopoulou C, Vergote I, Richter R, Cacsire Castillo-Tong D, Cadron I, Mahner S, Trillsch F, Concin N, Chekerov R, et al.: Interval (IDS) versus primary tumor debulking surgery (PDS) in advanced ovarian cancer (AOC): results from European OVCAD study. Int J Gynecol Cancer 2012, 22(3):E275.
• [24]Extermann M, Hurria A: Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007, 25:1824-1831.
• [25]Audisio RA, Pope D, Ramesh HS, Gennari R, van Leeuwen BL, West C, Corsini G, Maffezzini M, Hoekstra HJ, Mobarak D, et al.: Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008, 65:156-163.
• [26]Freyer G, Tinker AV: Clinical trials and treatment of the elderly diagnosed with ovarian cancer. Int J Gynecol Cancer 2011, 21:776-781.
• [27]Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999, 341:2061-2067.
• [28]Moonesinghe SR, Mythen MG, Grocott MP: High-risk surgery: epidemiology and outcomes. Anesth Analg 2011, 112:891-901.